NCT05767346
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
See it on ClinicalTrials.gov ↗175 people
41.7%
58.3%
73 womenmiddle line = equal numbers102 men
- Phase
- PHASE3
- Paid for by
- Cytokinetics
- Finished
- 2025-03-28
- Health conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 57.7 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 80% · Asian 14.3% · Not reported 4% · Other 1.1% · Black / African American 0.6% · Native Hawaiian / Pacific Islander 0% · American Indian / Alaska Native 0%
Women left out
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“Body mass index \< 35 kg/m2”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Significant valvular heart disease”
Study titles and rules are shown in their original English.